

Electronic Acknowledgement Receipt

EFS ID:	8645712
Application Number:	10719493
International Application Number:	
Confirmation Number:	3218
Title of Invention:	Methods of treating cancer using immunostimulatory oligonucleotides
First Named Inventor/Applicant Name:	Arthur M. Krieg
Correspondence Address:	Helen C. Lockhart, Ph.D. Wolf, Greenfield & Sacks, P.C. 600 Atlantic Avenue - Boston MA 02210 US 6177203500 hlockhart@wolfgreen.com
Filer:	Helen C. Lockhart/Paula Bramwell
Filer Authorized By:	Helen C. Lockhart
Attorney Docket Number:	C1039.70021US01
Receipt Date:	18-OCT-2010
Filing Date:	21-NOV-2003
Time Stamp:	16:25:31
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$1290

RAM confirmation Number		2907			
Deposit Account		232825			
Authorized User		LOCKHART,HELEN C			
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	C103970021US01-TRN-HCL.pdf	48786 8d85807cc44ff021edf23idda3c8108c35f1e5f8d9	no	1
Warnings:					
Information:					
2	Fee Worksheet (PTO-875)	C103970021US01-FEE-HCL.pdf	70522 32b6bc524aef270a2d567ad0bb3cfa8018fcd1c7da	no	1
Warnings:					
Information:					
3	Extension of Time	C103970021US01-EXT-HCL.pdf	55590 e138f90c3d8d40335d41c3ab5d465610d8b5cde8a7	no	1
Warnings:					
Information:					
4		C103970021US01-AMN-HCL.pdf	556479 8d682b05ad77b2b2ef8c30430b302ae070c9d94	yes	12
	Multipart Description/PDF files in .zip description				
	Document Description	Start		End	
	Amendment/Req. Reconsideration-After Non-Final Reject	1		1	
	Claims	2		5	
	Applicant Arguments/Remarks Made in an Amendment	6		12	
Warnings:					
Information:					
5	NPL Documents	Agrawal_et_al_Clin_Pharm_1995_v28_p7.pdf	692562 53003597a8ba6c6e15a13c1337b6ac308fd5920d4	no	10
Warnings:					
Information:					
6	NPL Documents	Agrawal_et_al_PNAS_1991_v88_p7595.pdf	315434 c29afed3c7b359002f15c501729228ee080ff7d5c	no	5

Warnings:					
Information:					
7	NPL Documents	Agrawal_Tibtech_1996_v14_p376.pdf	894569 378eb15867816d8f8d91ec5ad6514c5413a381	no	13
Warnings:					
Information:					
8	NPL Documents	Brody_et_al_J_Clin_Oncol_2010_v28_p4324.pdf	11356621 378b2ae49811c96d78740b7d9edaae1ef0cd4f73	no	10
Warnings:					
Information:					
9	NPL Documents	Flieger_FDA_Consumer_report_1995_7_pages.pdf	549939 d0f8dc6dd6392c53cb371413a65e7819eb138f8	no	7
Warnings:					
Information:					
10	NPL Documents	Hofmann_et_al_J_Immunother_2008_v31_p520.pdf	9781376 88c6d28591628d6e75d8a22c0c03c085aac3b	no	8
Warnings:					
Information:					
11	NPL Documents	Kim_et_al_Blood_2004_v104_Abst_743.pdf	117897 32b2c9c6d8188764180f718a93ae21e0c321e	no	2
Warnings:					
Information:					
12	NPL Documents	Leonard_et_al_Clin_Cancer_Research_2007_v13_p6168.pdf	7163971 0fb092418ee1ed0075db5c55eac918beb5d8bc6	no	7
Warnings:					
Information:					
13	NPL Documents	Link_et_al_J_Immunother_2006_v29_p558.pdf	12098974 731ad4999ad1a5e3398a24f763c0e0dad44c0c23	no	11
Warnings:					
Information:					
14	NPL Documents	Manegold_et_al_J_Clin_Oncol_v26_p3979.pdf	8081579 526f4bedc0f5c6dbf962012b93948ec0c99840	no	8
Warnings:					
Information:					
15	NPL Documents	Pashenkov_et_al_J_Clin_Oncol_2006_v24_p5716.pdf	9151450 d768a2ed6ed386ba3a6f05358bec07d24dab40	no	9

Warnings:					
Information:					
16	NPL Documents	Speiser_et_al_J_Clin_Invest_2005_v115_p739.pdf	638165 708abddfa1459ab24ebac1ac01d7d6f6c528ba72c	no	8
Warnings:					
Information:					
17	NPL Documents	Tokunaga_et_al_Jpn_J_Infect_Dis_1999_v52_p1.pdf	951217 d16d78c3c51db0515c5f9326c8d1c5d4585dd	no	12
Warnings:					
Information:					
18	NPL Documents	Vlassov_et_al_CRC_Press_1995_ch5_p71.pdf	3246257 53ba8ec6d12ab5c0064d8db0c2310d09307b	no	13
Warnings:					
Information:					
19	NPL Documents	C103970074US00_OA_mailed_04-14-2009.pdf	9847334 ca1db1a2ab049fb278255881096e40ee180ac	no	10
Warnings:					
Information:					
20	NPL Documents	C103970074US00_OA_mailed_11-19-2009.pdf	13891175 531e08617db165f7c752817116c27215ca78c26	no	14
Warnings:					
Information:					
21		C103970021US01-IDS-HCL.pdf	238212 1b1f865266228113c5f5158c257f16b0cc19e85e	yes	5
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	3	
	Information Disclosure Statement (IDS) Filed (SB/08)		4	5	
Warnings:					
Information:					
22	Fee Worksheet (PTO-875)	fee-info.pdf	32304 abc166591a12f83d3dab07fc1bb4c9f35d0f804bb	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			89780413		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.